Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors
- 8 October 2019
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (1) , e28028
Abstract
Background: The use of next‐generation sequencing for fusion identification is being increasingly applied and aids our understanding of tumor biology. Some fusions are responsive to approved targeted agents, while others have future potential for therapeutic targeting. Although some pediatric central nervous system tumors may be cured with surgery alone, many require adjuvant therapy associated with acute and long‐term toxicities. Identification of targetable fusions can shift the treatment paradigm toward earlier integration of molecularly targeted agents.Methods: Patients diagnosed with glial, glioneuronal, and ependymal tumors between 2002 and 2019 were retrospectively reviewed for fusion testing. Testing was done primarily using the ArcherDx FusionPlex Solid Tumor panel, which assesses fusions in 53 genes. In contrast to many previously published series chronicling fusions in pediatric patients, we compared histological features and the tumor classification subtype with the specific fusion identified.Results: We report 24 cases of glial, glioneuronal, or ependymal tumors from pediatric patients with identified fusions. With the exception ofBRAF:KIAA1549and pilocytic/pilomyxoid astrocytoma morphology, and possiblyQKI‐MYBand angiocentric glioma, there was not a strong correlation between histological features/tumor subtype and the specific fusion. We report the unusual fusions ofPPP1CB‐ALK,CIC‐LEUTX, FGFR2‐KIAA159, andMN1‐CXXC5and detail their morphological features.Conclusions: Fusion testing proved to be informative in a high percentage of cases. A large majority of fusion events in pediatric glial, glioneuronal, and ependymal tumors can be identified by relatively small gene panels.Keywords
Funding Information
- University of Colorado Denver
- National Cancer Institute (P30‐CA046934)
- Morgan Adams Foundation
This publication has 39 references indexed in Scilit:
- Fusion genes withALKas recurrent partner in ependymoma-like gliomas: a new brain tumor entity?Neuro-Oncology, 2015
- Distinct transcriptional signature and immunoprofile of CIC‐DUX4 fusion–positive round cell tumors compared to EWSR1‐rearranged ewing sarcomas: Further evidence toward distinct pathologic entitiesGenes, Chromosomes and Cancer, 2014
- Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumorsCancer Genetics, 2014
- BRAF alterations in pediatric low grade gliomas and mixed neuronal–glial tumorsJournal of Neuro-Oncology, 2013
- Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemiaProceedings of the National Academy of Sciences, 2013
- Discovering chimeric transcripts in paired-end RNA-seq data by using EricScriptBioinformatics, 2012
- Integrative genomics viewerNature Biotechnology, 2011
- Spectrum of Pilomyxoid AstrocytomasAmerican Journal of Surgical Pathology, 2010
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous SclerosisNew England Journal of Medicine, 2010
- Fast and SNP-tolerant detection of complex variants and splicing in short readsBioinformatics, 2010